Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Accumulated Expenses (2018 - 2025)

Tg Therapeutics (TGTX) has 8 years of Other Accumulated Expenses data on record, last reported at $2.1 million in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 54.1% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $2.1 million, down 54.1%, while the annual FY2025 figure was $2.1 million, 54.1% down from the prior year.
  • Other Accumulated Expenses reached $2.1 million in Q4 2025 per TGTX's latest filing, up from $2.0 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $14.5 million in Q1 2021 and bottomed at $807000.0 in Q3 2022.
  • Average Other Accumulated Expenses over 5 years is $4.0 million, with a median of $2.1 million recorded in 2025.
  • Peak YoY movement for Other Accumulated Expenses: plummeted 93.61% in 2022, then surged 232.84% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $1.5 million in 2021, then fell by 22.69% to $1.2 million in 2022, then rose by 26.52% to $1.5 million in 2023, then skyrocketed by 212.85% to $4.6 million in 2024, then tumbled by 54.1% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $2.1 million in Q4 2025, $2.0 million in Q3 2025, and $2.3 million in Q2 2025.